SCHEDULE 13D/A: Psyence Group Inc. Discloses 14.99% Beneficial Ownership in Psyence Biomedical Ltd. Following Strategic Transactions

Psyence Group Inc. has filed an amended Schedule 13D, revealing a 14.99% beneficial ownership stake in Psyence Biomedical Ltd., primarily through a business combination and the acquisition of Psyence Labs Ltd.

Summary

• Psyence Group Inc. (PGI) has filed an amended Schedule 13D, reporting beneficial ownership of 678,722 Common Shares of Psyence Biomedical Ltd. (the "Issuer").
• This ownership represents approximately 14.99% of the Issuer's outstanding Common Shares, based on 4,527,128 shares outstanding as of March 20, 2025.
• The shares were acquired through a series of transactions, including a Business Combination Agreement (BCA) that closed on January 25, 2024, where PGI received 66,666 Common Shares.
• Additionally, PGI acquired shares through the sale of its 11.13% stake in Psyence Labs Ltd. to the Issuer, which involved an initial issuance of 26,667 Common Shares on October 28, 2024, and a subsequent "make-whole payment" of 257,021 Common Shares on December 17, 2024.
• All share figures are presented on a post-split basis, following a 75-to-1 reverse stock split effective November 26, 2024.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13D) reporting beneficial ownership and related transactions. It is neutral in tone, providing required disclosures without expressing explicit positive or negative sentiment regarding the company's performance or outlook. The 'make-whole' payment could be seen as a slight negative for the issuer's share price performance, but the filing itself is purely informational.

Positives

• The filing indicates a significant strategic investment by Psyence Group Inc. in Psyence Biomedical Ltd., potentially aligning interests and fostering collaboration within the psychedelic life sciences sector.
• The "make-whole payment" mechanism in the Psylabs acquisition agreement protected Psyence Group Inc.'s valuation in the event of a share price decline, demonstrating a favorable term for the seller.

Negatives

• The need for a "make-whole payment" suggests that the share price of Psyence Biomedical Ltd. (the Issuer) declined below the agreed-upon $41.25 per share valuation for the Psylabs acquisition, indicating potential share price volatility or underperformance.

Risks

• The value of Psyence Group Inc.'s investment in Psyence Biomedical Ltd. is subject to the market fluctuations of Psyence Biomedical Ltd.'s Common Shares.
• The "make-whole payment" clause highlights the risk of share price volatility for Psyence Biomedical Ltd., which could impact future transactions or valuations.

Future Outlook

The document does not contain explicit forward-looking statements or guidance regarding the future operations or financial performance of either Psyence Group Inc. or Psyence Biomedical Ltd. beyond the terms of the existing agreements.

Industry Context

Psyence Group Inc. is a life science biotechnology company focused on natural psychedelics, listed on the Canadian Securities Exchange (CSE:PSYG). Psyence Biomedical Ltd. operates in a similar space, indicating a strategic alignment within the burgeoning psychedelic-based therapeutics and research industry. This filing reflects consolidation or strategic investment within this niche, where companies are seeking to leverage synergies and expand their intellectual property or operational footprint.

Comparison to Industry Standards

• This Schedule 13D filing is a standard regulatory disclosure for significant beneficial ownership.
• The specific terms of the business combination and the Psylabs acquisition, including the make-whole provision, are unique to the agreements between Psyence Group Inc. and Psyence Biomedical Ltd. and cannot be directly compared to general industry standards without specific details of comparable transactions in the psychedelic biotechnology sector.
• However, the 75-to-1 reverse stock split is a significant corporate action often undertaken by companies to increase their share price and meet listing requirements, a common practice across various industries.

Legal Proceedings

• Psyence Group Inc. has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• Psyence Group Inc. has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which it was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Related Party Transactions

• The acquisition of an 11.13% stake in Psyence Labs Ltd. by Psyence Biomedical Ltd. from Psyence Group Inc. can be considered a related party transaction, given that Psyence Group Inc. is now a significant beneficial owner of Psyence Biomedical Ltd.

Stakeholder Impact

• Shareholders of Psyence Biomedical Ltd. experienced dilution due to the issuance of Common Shares for the Psylabs acquisition and the subsequent make-whole payment.
• Shareholders of Psyence Group Inc. now have a significant equity stake in Psyence Biomedical Ltd., aligning their interests with the performance of the Issuer.

Next Steps

• The document does not explicitly state future actions or milestones beyond the completion of the described transactions.
• The Issuer is required to register the resale of the Common Shares issued in the Psylabs acquisition, as set forth in the Psylabs Purchase Agreement.

Key Dates

Keywords

Psyence Group Inc., Psyence Biomedical Ltd., Schedule 13D, beneficial ownership, common shares, business combination, Psylabs acquisition, reverse stock split, psychedelics, biotechnology, life science, SEC filing, equity stake, make-whole payment